| 
                                
                                    |   |  |  
                                    | 
 |  
                                    | Effective Date: 09/18/1995 | Title: Fetal Surgery in Utero |  
                                    | Revision Date: 10/01/2015 | Document: BI115:00 |  
                                    | CPT Code(s): 59070, 59072, 59074, 59076, 59897 
 |  
                                    | Public Statement 
 |  
                                    | 
Effective Date:
 
a)   
This policy 
will apply to all services performed on or after the above revision date which 
will become the new effective date. 
b)   
For all 
services referred to in this policy that were performed before the revision 
date, contact customer service for the rules that would apply. 
Surgical 
procedures on the unborn fetus are high profile interventions, but have mostly 
not been shown to be scientifically supportable. Most such procedures are still 
considered by QualChoice to be experimental or investigational.  
 |  
                                    | Medical Statement 
 |  
                                    | 
	
	In utero 
	fetal surgery is considered medically necessary for any of the 
	following indications: 
	
		
		
		Amnioinfusion (59070) as treatment of oligohydramnios (P01.2);
		
		Vesico-amniotic shunting (59076) as a treatment of urinary tract 
		obstruction (Q64.31-Q64.39);
		In 
		utero resection of malformed pulmonary tissue (59897), or 
		placement of a thoraco-amniotic shunt (59076) as a treatment of 
		either of the following: 
		
			
			
			congenital cystic adenomatoid malformation (Q89.9); or 
			
			
			extra lobar pulmonary sequestration (Q33.2 - Q33.3, Q33.6); 
			
		In 
		utero removal of sacro-coccygeal teratoma (59897) (O33.7). 
	
	QualChoice considers the following applications of in utero fetal surgery 
	experimental and investigative: 
	
		
		Laser 
		ablation of anastomotic vessels (59897) in twin-twin transfusion  
		syndrome (O43.021-O43.029); 
		In 
		utero repair of neural tube defects (59897) for spinabifida (O35.0XX1 - 
		 O35.0XX9); Fetal tracheal occlusion (59897) for congenital 
		diaphragmatic hernia (Q79.0) 
		
		Surgical repair of diaphragmatic hernia (Q79.0, Q79.1).
	
	QualChoice considers other applications of in utero surgery experimental and 
	investigative.  
  
Codes Used In This BI: 
  
59070 
Transabdom Amnioinfus w/US 
59072 
Umbilical Cord Occlude w/US 
59074 Fetal 
Fluid Drainage w/US 
59076 Fetal 
Shunt Placement w/US 
59897 Fetal 
Invas PX w/US 
 |  
                                        | Background 
 |  
                                        | 
Fetal surgery 
in utero has been attempted for various congenital anomalies including 
congenital diaphragmatic hernia (CDH), spina bifida and urinary tract 
abnormalities. 
Congenital 
diaphragmatic hernia is a defect in the diaphragm of a developing fetus, which 
results in abdominal viscera protrusion into the chest, displacing the lungs and 
heart in the thoracic cavity. CDHs are usually repaired after delivery; however, 
two primary methods for treating CDH in utero have emerged in an attempt to 
overcome pulmonary hypoplasia and persistent pulmonary hypertension in infants 
who are more severely affected: (1) surgical repair of the herniated diaphragm, 
and (2) ligation of the fetal trachea, with subsequent stimulation of lung 
growth.  
  
Surgical 
treatment of spina bifida usually occurs within 24 hours of birth; however, in 
utero repair has been used as a method to decrease nerve damage and improve 
outcomes at birth. Lower urinary tract obstruction has a significant impact on 
neonatal and child health. Pulmonary hyperplasia and renal impairment could be 
direct or indirect consequences of this condition leading to significant 
morbidity and mortality. Vesico-amniotic fetal shunting, open fetal surgery and 
more recently endoscopic fetal surgery for this condition are available as 
possible options of fetal intervention. Vesico-amniotic shunting has the 
advantage of bypassing the obstruction, however it is often associated with 
complications. Open fetal surgery is not usually recommended because of the 
complications and high fetal loss rate. Endoscopic surgery to visualize and 
treat the cause of lower urinary tract obstruction has been tried. Fetal 
endoscopic surgery is in its infancy.  
  
Twin-twin 
transfusion syndrome is the most common complication of monochorionic 
pregnancies affecting between 5 and 15 % of such pregnancies and accounts for 15 
- 77 % of perinatal mortality in twins. No single therapy is associated with a 
uniformly improved outcome for the involved twins and success is primarily 
related to gestational age and severity at diagnosis. Treatment options for 
severe cases include digitalization, ligation of the umbilical cord, serial 
amniocenteses, septostomy, laser occlusion of placental vessels, and selective 
feticide. Other congenital anomalies that are amenable to in utero treatment 
include myelomeningocele, cystadenomatoid malformation of the lung and 
saccro-coccygeal teratoma, shunts for uropathies and thoracic fluids. 
  
Findings of 
recent studies indicated that the effectiveness of in utero approach in treating 
congenital diaphragmatic hernia (CDH) has not been established. Downard and 
Wilson (2003) noted that antenatal maternal steroid administration and fetal 
surgery are not proven interventions for CDH.. Adzick and Kitano (2003) stated 
that fetuses diagnosed with left CDH before 26 weeks` gestation with associated 
liver herniation and a low right lung to head circumference ratio have a reduced 
prognosis with conventional therapy after birth, but in utero therapeutic 
approaches have yet to show a comparative survival benefit. Adzik and Kitano 
stated that a prospective randomized trial is required to critically evaluate 
the efficacy of fetal tracheal occlusion for severe diaphragmatic hernia. Heerma, 
et al. (2003) reported on comparative autopsy in 16 cases of congenital 
diaphragmatic hernia with fetal intervention (12 cases tracheal occlusion; 4 
cases hernia repair) with 19 cases of congenital diaphragmatic hernia without 
fetal intervention. The investigators concluded that tracheal occlusion did not 
prevent development of lung pathology associated with pulmonary hypoplasia.
 
  
A prospective 
randomized controlled trial of fetal tracheal occlusion for congenital 
diaphragmatic hernia found no differences in outcomes between subjects assigned 
to fetal endoscopic tracheal occlusion or standard care (Harrison, et al., 
2003). Enrollment was stopped after 24 women carrying fetuses with severe 
congenital diaphragmatic hernia had been enrolled because of the unexpectedly 
high survival rate with standard care and the conclusion of the data safety 
monitoring board that further recruitment would not result in significant 
differences between the groups. Eight of 11 fetuses (73 percent) in the 
tracheal-occlusion group and 10 of 13 (77 percent) in the group that received 
standard care survived to 90 days of age. The authors concluded that tracheal 
occlusion did not improve survival or morbidity rates in this cohort of fetuses 
with congenital diaphragmatic hernia. In an accompanying editorial, Wenstrom 
(2003) argued that there are several reasons why antenatal tracheal occlusion 
may not result in a better outcome than conventional therapy. Wenstrom reasoned 
that, with new diagnostic technologies, congenital diaphragmatic defects of 
varying degrees of severity, from mild to severe, are now routinely identified 
antenatally, and affected neonates receive care at tertiary centers that offer 
highly specialized treatments for respiratory disease, including extracorporeal 
membrane oxygenation, high-frequency oscillatory ventilation, inhaled nitric 
oxide, exogenous surfactant, and others. As a result, the current survival rate 
for all cases of isolated congenital diaphragmatic hernia - from mild to severe 
- approaches 70 percent without fetal surgery, and neonates who do not require 
extracorporeal life support (approximately half of those with isolated 
congenital diaphragmatic hernia) have a survival rate of at least 80 percent. 
Wenstrom argued that another reason why antenatal intervention may not result in 
a better outcome than conventional therapy is that any potential benefit may be 
negated by the substantial fetal morbidity associated with the surgical 
procedure itself. Most pregnancies subjected to antenatal fetal surgery end in 
preterm delivery. Wenstrom noted that, in the study by Harrison et al., 
premature rupture of the membranes and preterm delivery occurred in 100 percent 
of those receiving antenatal treatment. The mean age at delivery was 30.8 weeks 
in the treated group, an age at which morbidity related to prematurity is 
likely. In addition, because birth occurred, on average, just six weeks after 
the procedure, appropriate catch-up lung growth may not yet have occurred. 
Wenstrom concluded that “[t]he study by Harrison et al. also illustrates the 
critical importance of randomized clinical trials in evaluating new therapies - 
even heroic procedures performed in only a small fraction of neonates - before 
they are adopted as part of standard practice.” 
  
A Hayes 
Medical Technology Directory Report published in October of 2012 reviewed the 
literature regarding intrauterine fetal surgery (IUFS) for congenital 
diaphragmatic hernia (CDH) through 2012, and concluded that there was 
insufficient evidence to support the practice.  Besides the literature noted 
above, two studies by Ruano et al from the same RCT were reviewed and compared 
to previous literature.  While Harrison’s study showed a 75% overall survival 
rate, Ruano showed a 50% survival in the IUFS group compared to a 4.8% survival 
in standard care.  It seems likely, then, that the reported survival advantage 
of IUFS in Ruano was a result of low survival in the control group rather than 
being evidence in favor of IUFS. 
 |  
                                        | Reference 
 |  
                                        | 
	
	Scott JR, Di Saia PJ, Hammond CB, 
	et al, eds. Danforth`s Obstetrics and Gynecology. Philadelphia, PA: 
	Lippincott Williams & Wilkins;1999:228-230. 
	Adzick NS, Sutton LN, Cromblehome 
	TM, et al. Successful fetal surgery for spina bifida. Lancet. 
	1998;352:1675-1676. 
	Quintero RA, Bornick PW, Allen MH, 
	Johnson PK. Selective laser photocoagulation of communicating vessels in 
	severe twin-twin transfusion syndrome in women with an anterior placenta. 
	2001;97(3):477-481. 
	Odibo AO, Macones GA. Management 
	of twin-twin transfusion syndrome: Laying the foundation for future 
	interventional studies. Twin Res. 2002;5(6):515-520. 
	Ropacka M, Markwitz W, Blickstein 
	I. Treatment options for the twin-twin transfusion syndrome: A review. Twin 
	Res. 2002;5(6):507-514. 
	Evans MI, Harrison MR, Flake AW, 
	Johnson MP. Fetal therapy. Best Pract Res Clin Obstet Gynaecol. 
	2002;16(5):671-683. 
	Coleman BG, Adzick NS, Crombleholme TM, et al. 
	Fetal 
	therapy: State of the art. J Ultrasound Med. 2002;21(11):1257-1288. 
	
	Quintero RA, Martinez JM, Bermudez C, et al. 
	
	Fetoscopic demonstration of perimortem feto-fetal hemorrhage in twin-twin 
	transfusion syndrome. Ultrasound Obstet Gynecol. 2002;20(6):638-639. 
	
	Quintero RA, Dickinson JA, Morales WJ, et al. 
	
	Stage-based treatment of twin-twin transfusion syndrome. Am J Obstet 
	Gynecol. 2003;188(5):1333-1340. 
	Tsao K, Albanese CT, Harrison MR. 
	Prenatal therapy for thoracic and mediastinal lesions. World J Surg. 
	2003;27(1):77-83. 
	Martinez JM, Bermudez C, Becerra C, et al. 
	The role 
	of Doppler studies in predicting individual intrauterine fetal demise after 
	laser therapy for twin-twin transfusion syndrome. Ultrasound Obstet Gynecol. 
	2003;22(3):246-251. 
	Walsh DS, Adzick NS. Fetal 
	surgery for spina bifida. Semin Neonatal. 2003;8(3):197-205. 
	Adzick NS, Kitano Y. Fetal 
	surgery for lung lesions, congenital diaphragmatic hernia, and 
	sacro-coccygeal teratoma. Semin Pediatric Surg. 2003;12(3):154-167. 
	
	Sydorak RM, Harrison MR. 
	Congenital diaphragmatic hernia: Advances in prenatal therapy. Clin 
	Perinatal. 2003;30(3):465-479. 
	Au-Yeung JY, Chan KL. Prenatal 
	surgery for congenital diaphragmatic hernia. Asian J Surg. 
	2003;26(4):240-243. 
	Downard CD, Wilson JM. Current 
	therapy of infants with congenital diaphragmatic hernia. Semin Neonatal. 
	2003;8(3):215-221. 
	Harrison MR, Keller RL, Hawgood 
	SB, et al. A randomized trial of fetal endoscopic tracheal occlusion for 
	severe fetal congenital diaphragmatic hernia. N Engl J Med. 
	2003;349(20):1916-1924. 
	Heerema AE, Rabban JT, Sydorak 
	RM, et al. Lung pathology in patients with congenital diaphragmatic hernia 
	treated with fetal surgical intervention, including tracheal occlusion. 
	Pediatric Dev Pathol. 2003 Nov 5 [Epub ahead of print] 
	Wenstrom 
	KD. Fetal surgery for congenital diaphragmatic hernia. N Engl J Med. 
	2003;349(20):1887-1888. 
	Ruano R, 
	Yoshisake CT, da Silva MM, et al.  A randomized controlled trial of fetal 
	endoscopic tracheal occlusion versus postnatal management of severe isolated 
	congenital diaphragmatic hernia.  Ultrasound Obstet Gynecol. 
	2012;39(1):20-27
	Ruano R, 
	da Silva MM, Campos JA, et al.  Fetal pulmonary response after fetoscopic 
	tracheal occlusion for severe isolated congenital diaphragmatic hernia. 
Obstet Gynecol. 
2012a;119(1):93-101. 
	
	Hayes 
	Medical Technology Report.  In Utero Fetal Surgery for Congenital 
	Diaphragmatic Hernia.  Published October 23, 2012, accessed October 29, 
	2012. 
 |  
                                    | Application to Products 
 |  
                                    | This policy applies to all health plans administered by QualChoice, both those insured by QualChoice and those that are self-funded by the sponsoring employer, unless there is indication in this policy otherwise or a stated exclusion in your medical plan booklet.  Consult the individual plan sponsor Summary Plan Description (SPD) for self-insured plans or the specific Evidence of Coverage (EOC) for those plans insured by QualChoice.  In the event of a discrepancy between this policy and a self-insured customer’s SPD or the specific QualChoice EOC, the SPD or EOC, as applicable, will prevail.  State and federal mandates will be followed as they apply. 
 |  
                                    | Changes: QualChoice reserves the right to alter, amend, change or supplement benefit interpretations as needed. |  |